Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03858231 |
Recruitment Status :
Recruiting
First Posted : February 28, 2019
Last Update Posted : January 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Knee Injuries Pain, Postoperative Opioid Use | Drug: Norco 5Mg-325Mg Tablet Drug: Ibuprofen 600 mg Drug: Acetaminophen 325Mg Tab | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 300 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | The Effects of Combination Therapy of Opioids Versus Non-Opioids on Postoperative Pain Management After Knee Arthroscopic Surgery: A Prospective Randomized Controlled Study |
Actual Study Start Date : | October 29, 2018 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | January 2021 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Opioid |
Drug: Norco 5Mg-325Mg Tablet
1 tablet up to 4 times per day for 7 days |
Active Comparator: Non-opioid |
Drug: Ibuprofen 600 mg
1 tablet up to 4 times per day for 7 days Drug: Acetaminophen 325Mg Tab 1 tablet up to 4 times per day for 7 days |
- Change from Baseline Pain Assessment at 2 weeks [ Time Frame: Daily for 2 weeks post-operatively ]Visual Analog Scale from 0 to 10 with 0 being no pain and 10 being worst possible, unbearable, excruciating pain
- Change from Baseline Medication Use at 2 weeks [ Time Frame: Daily for 14 days post-operatively ]Patients will be asked how many study medication capsules have they taken.
- Change from Baseline Knee Injury and Osteoarthritis Outcome Score (KOOS) at 6 weeks [ Time Frame: baseline, 2 weeks, and 6 weeks post-operatively ]Sub-scales are listed as follows: 5 qualitative questions related to knee symptoms ranging from "never" to "always", 2 qualitative questions related to knee stiffness ranging from "none" to "extreme", 9 qualitative questions related to pain ranging from "none" to "extreme", 17 qualitative questions related to function and daily living ranging from "none" to "extreme", 5 qualitative questions related to function and sports and recreational activities ranging from "none" to "extreme", and 4 qualitative questions related to quality of life ranging from "never or not at all" to "constantly, totally, or extreme".
- Change from Baseline Patient Reported Outcome Measurement Information System (PROMIS) at 6 weeks [ Time Frame: baseline, 2 weeks, and 6 weeks post-operatively ]7 qualitative questions related to pain interference with responses ranging from "not at all" to "very much"

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects ≥ 18 years of age through ≤ 80 years of age
- Subjects undergoing elective arthroscopic knee surgery, to include partial meniscectomy, chondroplasty, or loose body removal.
Exclusion Criteria:
- Previously enrolled in this study (enrolled for contralateral knee in this study)
- Knee arthroscopy patients scheduled for knee ligament reconstructions
- Bilateral knee arthroscopy
- History of chronic opioid use or long-term analgesic therapy
- Documented or suspected substance abuse
- Currently on daily use of ibuprofen, acetaminophen or other pain altering medication, including medications like Neurontin (gabapentin) and Ultram (tramadol)
- Documented or suspected chronic pain syndrome
- Any known allergy or adverse reaction or contraindication to the components of hydrocodone, acetaminophen, or ibuprofen
- History or symptoms of any significant medical problem in the last year (i.e., arrhythmia, impaired cardiovascular function, gastrointestinal bleeding, liver disease, renal disease)
- With active peptic ulcer disease (history of severe heartburn)
- Symptoms of infection with initial enrollment
- Pregnant or nursing
- Diagnosis of cognitive impairment
- Unable or unwilling to provide informed consent for surgery or enrollment in this clinical study
- Inability to understand the requirements of the study or be unwilling to provide written informed consent (as evidenced by signature on an informed consent document approved by Institutional Review Board) and agree to abide by the study restrictions.
- Patient refusal
- Currently taking Coumadin, Plavix, anticoagulation medications, or medications that increase bleeding
- Patients with other medical or psychological health conditions that preclude them from either receiving the intervention or returning for follow-up visits.
- Alcoholism

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03858231
Contact: Amy Tuchscherer | (701) 417-6292 | amy.tuchscherer@sanfordhealth.org | |
Contact: Katie Jensen | (605) 312-6983 | Katie.E.Jensen@SanfordHealth.org |
United States, North Dakota | |
Sanford Health | Recruiting |
Fargo, North Dakota, United States, 58122 | |
Contact: Amy Tuchscherer 701-417-6292 amy.tuchscherer@sanfordhealth.org | |
Contact: Katie Jensen (605) 312-6983 Katie.E.Jensen@SanfordHealth.org | |
Principal Investigator: Bruce Piatt, MD |
Principal Investigator: | Bruce Piatt, MD | Sanford Health |
Responsible Party: | Sanford Health |
ClinicalTrials.gov Identifier: | NCT03858231 |
Other Study ID Numbers: |
SH Opioid Knee |
First Posted: | February 28, 2019 Key Record Dates |
Last Update Posted: | January 28, 2020 |
Last Verified: | January 2020 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Pain, Postoperative Knee Injuries Postoperative Complications Pathologic Processes Pain Neurologic Manifestations Leg Injuries Wounds and Injuries Acetaminophen Ibuprofen Analgesics, Non-Narcotic |
Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Antipyretics Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |